Vir Biotechnology, Inc. Operating Lease Right-of-Use Assets
Vir Biotechnology, Inc. (VIR) had Operating Lease Right-of-Use Assets of $59.39 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-05
- 2026-06-30: Operating Lease, Right-of-Use Asset $59.39M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $60.76M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $62.10M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $63.55M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $59.39M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $60.76M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $62.10M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $63.55M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $64.85M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $58.56M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $59.68M 10-K · filed 2026-02-23 |
| 2024-09-30 | $60.78M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $62.27M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $70.35M 10-Q · filed 2024-05-03 |
| 2023-12-31 | $71.18M 10-K · filed 2025-02-27 |
| 2023-09-30 | $72.62M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $74.93M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $81.50M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $82.56M 10-K · filed 2024-02-26 |
| 2022-09-30 | $84.72M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $86.88M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $88.33M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $87.22M 10-K · filed 2023-02-28 |
| 2021-09-30 | $57.57M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $58.97M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $60.46M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $61.95M 10-K · filed 2022-02-28 |
| 2020-09-30 | $14.76M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $15.18M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $16.01M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |